» Articles » PMID: 35350569

The Role of Histone Post-Translational Modifications in Merkel Cell Carcinoma

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Mar 30
PMID 35350569
Authors
Affiliations
Soon will be listed here.
Abstract

Merkel Cell Carcinoma (MCC) is a rare but highly aggressive form of non-melanoma skin cancer whose 5-year survival rate is 63%. Merkel cell polyomavirus (MCPyV), a small DNA tumor virus, is the etiological agent of MCC. Although representing a small proportion of MCC cases, MCPyV-negative MCCs have also been identified. The role of epigenetic mechanisms, including histone post-translational modifications (PTMs) in MCC, have been only partially determined. This review aims to describe the most recent progress on PTMs and their regulative factors in the context of MCC onset/development, providing an overview of current findings on both MCC subtypes. An outline of current knowledge on the potential employment of PTMs and related factors as diagnostic and prognostic markers, as well as novel treatment strategies targeting the reversibility of PTMs for MCC therapy is provided. Recent research shows that PTMs are emerging as important epigenetic players involved in MCC onset/development, and therefore may show a potential clinical significance. Deeper and integrated knowledge of currently known PTM dysregulations is of paramount importance in order to understand the molecular basis of MCC and improve the diagnosis, prognosis, and therapeutic options for this deadly tumor.

Citing Articles

Advancing Treatment Options for Merkel Cell Carcinoma: A Review of Tumor-Targeted Therapies.

Nammour H, Madrigal K, Starling C, Doan H Int J Mol Sci. 2024; 25(20).

PMID: 39456853 PMC: 11507330. DOI: 10.3390/ijms252011055.


Merkel cell carcinoma: updates in tumor biology, emerging therapies, and preclinical models.

Pedersen E, Verhaegen M, Joseph M, Harms K, Harms P Front Oncol. 2024; 14:1413793.

PMID: 39136002 PMC: 11317257. DOI: 10.3389/fonc.2024.1413793.


Morphological Changes Induced by TKS4 Deficiency Can Be Reversed by EZH2 Inhibition in Colorectal Carcinoma Cells.

Jacksi M, Schad E, Tantos A Biomolecules. 2024; 14(4).

PMID: 38672463 PMC: 11047920. DOI: 10.3390/biom14040445.


Editorial: Recent advances in diagnosis, prognosis, and therapy of oncogenic virus-driven tumors.

Tognon M, Martini F, Rotondo J, Fiume G Front Oncol. 2024; 14:1402877.

PMID: 38660129 PMC: 11040595. DOI: 10.3389/fonc.2024.1402877.


A Surprising Repurposing of Central Nervous System Drugs against Squamous Cell Carcinoma of the Bladder, UM-UC-5.

Gouveia M, Ribeiro E, Vale N Pharmaceutics. 2024; 16(2).

PMID: 38399266 PMC: 10892655. DOI: 10.3390/pharmaceutics16020212.


References
1.
Del Marmol V, Lebbe C . New perspectives in Merkel cell carcinoma. Curr Opin Oncol. 2019; 31(2):72-83. DOI: 10.1097/CCO.0000000000000508. View

2.
Murakami I, Wada N, Nakashima J, Iguchi M, Toi M, Hashida Y . Merkel cell polyomavirus and Langerhans cell neoplasm. Cell Commun Signal. 2018; 16(1):49. PMC: 6103986. DOI: 10.1186/s12964-018-0261-y. View

3.
Luger K, Mader A, Richmond R, Sargent D, Richmond T . Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature. 1997; 389(6648):251-60. DOI: 10.1038/38444. View

4.
Liu J, Zhao H, Zhang Q, Shi Z, Zhang Y, Zhao L . Human papillomavirus type 16 E7 oncoprotein-induced upregulation of lysine-specific demethylase 5A promotes cervical cancer progression by regulating the microRNA-424-5p/suppressor of zeste 12 pathway. Exp Cell Res. 2020; 396(1):112277. DOI: 10.1016/j.yexcr.2020.112277. View

5.
Sheng W, LaFleur M, Nguyen T, Chen S, Chakravarthy A, Conway J . LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. Cell. 2018; 174(3):549-563.e19. PMC: 6063761. DOI: 10.1016/j.cell.2018.05.052. View